This study is testing a combination of two oral drugs, avutometinib and defactinib, for women with recurrent low-grade serous ovarian cancer (LGSOC) that has worsened after platinum-based chemotherapy. These drugs are kinase inhibitors, which work by blocking cancer cell growth. The study compares this combination to standard treatments like pegylated liposomal doxorubicin, paclitaxel, or letrozole. To join, you must have LGSOC and your tumor's KRAS status must be known. The main goal is to see if the avutometinib and defactinib combination can prevent the cancer from growing or spreading for longer (progression-free survival). The study is currently recruiting 270 participants, but its exact status is unclear.

Study design

This is an international, randomized, open-label, Phase 3 study. It will compare the investigational combination of avutometinib plus defactinib versus standard treatments in about 270 participants.

What's involved

Participants will receive either the investigational drug combination or one of the standard treatments. There will be subsequent follow-up appointments.

Compensation

Not stated in the trial record.

Follow-up

The main measure of success, progression-free survival, will be assessed for up to 24 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.